Cephalin form bovine brain

Name: Cephalin form bovine brain
Brand: MedChemExpress
SKU: HY-W250118
Rating: 5.0 (2 reviews)

Cat. No.: HY-W250118 Purity: 98.0%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Cephalin form bovine brain is an orally active phospholipid widely present in organisms.Cephalin form bovine brain participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Cephalin form bovine brain enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity.

For research use only. We do not sell to patients.

CAS No. : 90989-93-8

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

2 Publications Citing Use of MCE Cephalin form bovine brain

Cell Proliferation/Viability Assay

: Cephalin form bovine brain purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 14:e17330. [Abstract]; Addition of GPLs (PCs, PEs, LysoPCs, and LysoPAs; each at 10 µg/mL) to EAC cells for 5 days attenuated the inhibitory effect of TRIM15 knockdown or FOXRED1 overexpression on cell proliferation.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Cephalin form bovine brain (DHA-containing) (50 μM, 72-h co-treatment with dbcAMP) combined with dbcAMP enhances cell differentiation and growth inhibition of HL-60 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cephalin form bovine brain (375 mg/kg; i.p.) significantly inhibits food intake and locomotor activity in mice^[4].
Cephalin form bovine brain (2 g added to the basal diet containing 8 g of soybean oil; p.o.; dietary administration; ad libitum; 15-18 days) causes a decrease in serum cholesterol, phospholipid, apolipoprotein A-I (apoA-I) and apoE, an increase in high molecular weight apoB, alters the distribution of hepatic phospholipids and the fatty acid composition of serum and hepatic phospholipids in rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (weight: 143 g, specific age not mentioned) fed cholesterol-free semipurified diet^[6]
Dosage:	2 g of Phosphatidylethanolamine added to the basal diet containing 8 g of soybean oil
Administration:	Dietary administration, ad libitum, 15-18 days
Result:	Led to a significant decrease in serum cholesteryl ester, phospholipid, apoA-I and apoE, while serum apoB was higher compared to the PC and control groups. Decreased hepatic cholesterol. Altered the relative distribution of phospholipid subclasses in the liver. Altered the fatty acid composition of liver PC and PE. Enhanced the excretion of fecal neutral steroids. Showed higher hepatic HMG-CoA reductase activity.

CAS No.

90989-93-8

Appearance

Oil

Color

Light yellow to yellow

SMILES

[Cephalin form bovine brain]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

Ethanol : 50 mg/mL (Need ultrasonic)

DMSO : 5 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.0%

Select Batch:

Data Sheet (271 KB) SDS (788 KB)

COA (241 KB)

Handling Instructions (2659 KB)

References

[1]. Rockenfeller P, et al. Phosphatidylethanolamine positively regulates autophagy and longevity. Cell Death Differ. 2015 Mar;22(3):499-508. [Content Brief]

[2]. Ishigamori H, et al. Docosahexaenoic acid-containing phosphatidylethanolamine enhances HL-60 cell differentiation by regulation of c-jun and c-myc expression. Mol Cell Biochem. 2005 Jul;275(1-2):127-33. [Content Brief]

[3]. Cohen BC, et al. Lipid Droplet Fusion in Mammary Epithelial Cells is Regulated by Phosphatidylethanolamine Metabolism. J Mammary Gland Biol Neoplasia. 2017 Dec;22(4):235-249. [Content Brief]

[4]. Wellner N, et al. Studies on the anorectic effect of N-acylphosphatidylethanolamine and phosphatidylethanolamine in mice. Biochim Biophys Acta. 2011 Sep;1811(9):508-12. [Content Brief]

[5]. Li Z, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006 May;3(5):321-31. [Content Brief]

[6]. Imaizumi K, et al. The contrasting effect of dietary phosphatidylethanolamine and phosphatidylcholine on serum lipoproteins and liver lipids in rats. J Nutr. 1983 Dec;113(12):2403-11. [Content Brief]

[7]. Imaizumi K, et al. Effect of phosphatidylethanolamine and its constituent base on the metabolism of linoleic acid in rat liver. Biochim Biophys Acta. 1989 Oct 17;1005(3):253-9. [Content Brief]